Is It Time to Dump Your Shares of Eli Lilly?

Eli Lilly’s GLP-1 franchise (Mounjaro and Zepbound) drove a 46% year‑over‑year revenue increase through the first three quarters of 2025 and accounted for 54% of company revenue through the first nine months of 2025, but faces competitive and patent risks as Novo Nordisk has launched a pill formulation and other firms (Pfizer, Chinese partners) pursue oral GLP‑1s. Management is redeploying GLP‑1 windfalls into acquisitions (Adverum, late 2025; Ventyx, early 2026) to diversify the pipeline, yet the stock is trading at a stretched 52x P/E versus the S&P 500’s ~28.4 and the average pharma ~10x, prompting a cautious sell/trim view unless Lilly can defend market share or replace GLP‑1 revenues. Investors should weigh near‑term competitive threats to dosing convenience and long‑term patent cliff risk against the current valuation premium.

Analysis

Market structure: Novo Nordisk (NVO) and any approved oral GLP‑1s (including Pfizer partnerships) are clear near‑term winners — pills lower switching friction and can take share quickly from Eli Lilly’s (LLY) injectables, which represent ~54% of LLY revenue through 9M‑2025. LLY’s high P/E (52x) already prices clinical/competitive defence; a 5–15ppt share loss in GLP‑1 sales over 12–24 months would meaningfully reduce EPS and justify multiple compression.

Risk assessment: Tail risks include rapid payer pricing interventions (single‑digit % price cuts nationally), FDA/advisory setbacks for oral formulations, or faster generic entry if patents are legally challenged; any of these could remove >20–30% of expected GLP‑1 cashflows within 3 years. Immediate risk (days–weeks) centers on headline adoption/coverage announcements; medium term (3–12 months) on market‑share data; long term (3–5 years) on patent cliffs and realised pipeline M&A outcomes (Adverum/VTYX integrations).

Trade implications: Implement a hedge: short LLY vs long NVO to capture pill adoption and valuation gap (delta‑neutral notional, 3–6 month horizon). Use options to limit capital — buy 6‑month LLY put spreads (30–45% OTM) sized to protect 1–2% portfolio exposure and buy 6–12 month NVO call spreads (15–25% OTM) funded by selling nearer‑dated premium. Reallocate 1–3% from LLY into diversified large‑cap pharma (e.g., PFE) to lower idiosyncratic GLP‑1 risk.

Contrarian angles: Consensus underestimates LLY’s M&A pipeline as a partial offset; successful integration of Adverum/VTYX could recover 10–20% of lost GLP‑1 revenue within 24–36 months if late‑stage readouts succeed. The market may be overpricing near‑term downside (selloff risk) but underpricing multi‑year regulatory/payer outcomes; nimble, horizon‑specific trades (3–12 months) capture adoption dynamics while avoiding binary long‑term pipeline outcomes.

Key Decisions for Investors

• Establish a pair trade: go 1–2% notional long NVO and 1–2% short LLY (equal dollar exposure) with a 3–6 month horizon to capture oral GLP‑1 adoption; hard stop if pair moves >12% adverse or after a major FDA/payer announcement.
• Buy a protective hedge on LLY: purchase 6‑month put spread (buy 35% OTM, sell 50% OTM) sized to insure 1–2% of portfolio value against a >20% downside; cost funded by selling 1–2 month covered calls on existing LLY position if held.
• Establish a 1–2% overweight in PFE (or equivalent diversified large‑cap pharma) within 30 days to reduce single‑name GLP‑1 exposure; increase if Pfizer announces positive oral GLP‑1 approvals/partnerships (trigger window 3–12 months).
• Reduce pure‑play GLP‑1 concentration: if LLY position >2% of portfolio, trim to 0.5–1.5% and redeploy proceeds into diversified healthcare ETFs (e.g., XLV) or cash for redeployment around clinical/payer catalysts over next 60–120 days.